SLC6A1 Disorder Review Covers Symptoms And New Treatments

What was studied

This paper was a scoping review, which means the authors gathered and summarized published research rather than testing a treatment in one new group of patients. They searched major medical databases, ClinicalTrials.gov, reference lists, and epilepsy conference abstracts through March 2026.

The review focused on people with SLC6A1-related neurodevelopmental disorder, a genetic condition caused by pathogenic heterozygous loss-of-function variants in the SLC6A1 gene. The paper mapped what is known about symptoms, seizure types, development and behavior, and possible treatments, including standard seizure medicines, diet therapy, and newer disease-targeted approaches.

What they found

The review found that epilepsy is very common in this condition, affecting about 90% of clinically identified people. Seizures usually began between about 14 months and 5 years of age. The most common seizure types were absence seizures, myoclonic-atonic seizures, and atonic seizures.

Developmental delay or intellectual disability was reported in 82% to 100% of patients, and in more than 60% of cases, thinking or learning problems started before seizures. Autistic features were reported in 22% to 65% of patients, and low muscle tone in 60% to 71%.

The review also reported that more severe loss of GAT-1 function was associated with more severe clinical problems, with variants showing near-total loss of GABA uptake being enriched in severe phenotypes. For treatment, valproate was described as the most consistently effective antiseizure medicine, with lamotrigine, clobazam, and ethosuximide also reported as helpful. Levetiracetam was often used, but the authors said behavioral side effects should be monitored. The ketogenic diet and acetazolamide were described as evidence-supported add-on options.

For newer therapies, 4-phenylbutyrate was highlighted because it restores GAT-1 trafficking in endoplasmic reticulum-retained variants. In the largest treated clinical cohort mentioned, 80% had seizure reduction and 40% became seizure-free. Gene replacement therapy using AAV9 normalized electroencephalography abnormalities in preclinical models, and the first early-phase human trial had dosed its initial patient.

Limits of the evidence

Because this was a scoping review, it summarizes available reports but does not establish which treatments work best. The evidence was described as fragmented, and the abstract says there are no randomized controlled trials yet.

Some findings likely come from small studies, case series, or conference abstracts, which can be less reliable than larger planned studies. The review also notes missing prospective natural history data, lack of standardized outcomes, and limited information about adults with this condition.

The treatment results for 4-phenylbutyrate and gene therapy are promising, but they are still early. The abstract does not give full details about how many patients were studied for each treatment, how long they were followed, or how durable benefits were.

For families and caregivers

For families, this review helps show the overall pattern of SLC6A1-related disorder: seizures are common, but learning, development, behavior, and muscle tone are also major parts of the condition. It also suggests that developmental concerns may appear before seizures in many children.

The paper may be useful when talking with a care team about treatment options that have been reported in the literature, such as valproate and sometimes the ketogenic diet or other add-on therapies. It also shows why families may hear about newer targeted treatments like 4-phenylbutyrate or gene therapy. Still, these newer approaches are not yet backed by strong trial evidence, so expectations should stay cautious.

What to watch next

Stronger evidence would come from larger prospective studies and randomized trials, and families can ask clinicians whether any registries or clinical trials for SLC6A1-related disorder are appropriate.

Terms in this summary

SLC6A1

A gene that gives instructions for making the GAT-1 protein.

GAT-1

A protein that helps move the brain chemical GABA back into cells after it sends a signal.

GABA

A brain chemical that usually helps calm nerve activity.

loss-of-function variant

A gene change that makes the gene or protein work less well or not work at all.

developmental and epileptic encephalopathy

A group of conditions with epilepsy plus developmental problems that can affect learning and behavior.

absence seizure

A brief seizure that may look like staring or a short pause in awareness.

ketogenic diet

A high-fat, very low-carbohydrate medical diet sometimes used to help control seizures.

randomized controlled trial

A study that compares treatments in a planned way, often giving the strongest evidence about what works.